Clinical Trial: A Study of Deucravacitinib to Treat LPP and FFA

Study Status: RECRUITING
Recruit Status: RECRUITING
Study Type: INTERVENTIONAL

Official Title: Deucravacitinib (BMS-986165) in the Treatment of Lichen Planopilaris

Brief Summary: The purpose of this clinical research study is to learn more about the use of Deucravacitinib in the treatment of Lichen Planopilaris.

Detailed Summary:
Sponsor: Mayo Clinic

Current Primary Outcome: Number of subjects to have complete or partial response to Deucravacitinib treatment as measured by Lichen Planopilaris Activity Index (LPPAI) score: complete response = LPPAI reduction greater than 85% from baseline score and partial response = LPPAI reduction between 25-85% from baseline score

Original Primary Outcome: Number of subjects to have complete or partial response to Deucravacitinib treatment as measured by Lichen Planopilaris Activity Index (LPPAI) score: complete response = LPPAI reduction greater than 85% from baseline score and partial response = LPPAI reduction between 25-85% from baseline score

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Mayo Clinic

Dates:
Date Received: October 16, 2023
Date Started: November 07, 2023
Date Completion: November 07, 2023
Last Updated: November 13, 2023
Last Verified: November 01, 2023